Crown BioScience experts explore organoid models and high-content imaging to evaluate T-cell-targeted therapies and ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have made a breakthrough in cancer ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses results from new data on the role of T cell dysfunction in ...

The immune system works to maintain homeostasis throughout the body. Various cell types and immune mechanisms work in concert ...

Mast cell activation syndrome, or disease (MCAS), is a condition that causes mast cells to release these substances too frequently, resulting in severe allergic reactions. After detecting an ...

Deletion of the plasma cell “marker” CD138 has no ... BCR engagement and T-cell help dictate CD138 and SDC4 expression and loss. Moreover, soluble GAGs restrained sensitivity to BCR-mediated ...

TOKYO :Tokyo-based investment firm Japan Activation Capital (JAC) said on Thursday it had closed its second fund at 77 billion yen ($511.93 million), bringing the total amount it has raised from ...

and 19CAR-T(8α)]. Through co-culture with tumor cells, we evaluate CAR dynamic change, activation levels, exhaustion markers, mitochondrial function, and differentiation in both CAR-T cells.